OH-GE-AEROSPACE
GE AEROSPACE (GENERAL ELECTRIC COMPANY; NYSE: GE) announced today that, as part of a simplification project following the launch of GE Aerospace as an independent public company, it has submitted applications for the delisting of GE common stock (ISIN Code US3696043013) from Euronext Paris, the London Stock Exchange and the SIX Swiss Exchange (the “Delisting”). This action follows a comprehensive review of the trading volume, cost and administrative requirements related to these listings. Following the Delisting, GE Aerospace shares will continue to be traded on the New York Stock Exchange (“NYSE”), GE Aerospace’s primary listing exchange.
The following required information is provided in connection with the Delisting from Euronext Paris. The Delisting has been approved by the Listing Board of Euronext Paris S.A.
Information Regarding Delisting Procedure for Euronext Paris
A sales facility procedure (the “Sales Facility”) will be put in place from 21 June 2024 to 19 July 2024 (the “Sales Facility Period”) to allow shareholders to sell on the NYSE their GE Aerospace shares which are listed on Euronext Paris and held in the Euroclear France clearing system (the “GE Aerospace Euronext Shares”). GE Aerospace has appointed Uptevia to act as centralizing agent under the Sales Facility (the “Centralizing Agent”).
During the Sales Facility Period, shareholders with GE Aerospace Euronext Shares will have the following options:
- sell on a voluntary basis all or part of their GE Aerospace Euronext Shares on the NYSE by participating in the Sales Facility (described in more detail below); or
- retain all or part of their GE Aerospace Euronext Shares, which will continue to be traded on Euronext Paris during the entire Sales Facility Period until and including the trading day prior to the date of the Delisting.
The GE Aerospace Euronext Shares will be delisted from Euronext Paris on 25 July 2024 (the “Delisting Date”).
Shareholders not participating
Shareholders who do not wish to sell their GE Aerospace Euronext Shares under the Sales Facility or directly on Euronext Paris, or have otherwise taken no action by the Delisting Date, will be able to trade their GE Aerospace Euronext Shares on the NYSE, subject to the terms and conditions applied by their financial intermediaries.
Participating shareholders
Shareholders who wish to sell their GE Aerospace Euronext Shares on the NYSE under the Sales Facility should request their financial intermediaries to deliver their GE Aerospace Euronext Shares during the Sales Facility Period to the Centralizing Agent, pursuant to the procedure described below.
The GE Aerospace Euronext Shares delivered to the Centralizing Agent during the Sales Facility Period will be sold on the NYSE as from 26 July 2024 by a broker, at market prices prevailing at the time of the sale. The Centralizing Agent will calculate the average sale price of the GE Aerospace Euronext Shares and will be in charge of transferring the sale proceeds (which will be converted into euros from U.S. dollars by Uptevia) to the GE Aerospace shareholders participating in the Sales Facility once it has received the funds for the sale of all of the GE Aerospace Euronext Shares tendered under the Sales Facility.
GE Aerospace will pay the brokerage commissions on the NYSE for the sale of GE Aerospace Euronext Shares tendered pursuant to the Sales Facility, the fee of the Centralizing Agent and any applicable foreign exchange commission that would be incurred in connection with the Sales Facility.
The Sales Facility procedure is also described in a Euronext notice to be published on 19 June 2024.
No guarantee can be given by GE Aerospace or by the Centralizing Agent as to the price at which the GE Aerospace Euronext Shares tendered pursuant to the Sales Facility will be sold. The Sales Facility is being provided solely as an accommodation to holders of GE Aerospace Euronext Shares. Holders (and in particular individual investors) of GE Aerospace Euronext Shares may decide not to participate in the Sales Facility or may decide not to take any action, in which case no guarantee can be given on the terms, including costs, that would be applied by their financial intermediary after the Delisting. Individual investors are urged to consult their own investment advisors before deciding to participate or not in this process.
The contemplated timetable of the Sales Facility and the Delisting can be summarized as follows (it being specified that GE Aerospace reserves the right to amend this calendar):
Event |
Date |
Sales Facility |
|
Beginning of the Sales Facility |
21 June 2024 |
End of the Sales Facility |
19 July 2024 |
End of the centralization by Uptevia |
23 July 2024 |
Sale on the NYSE of the GE Aerospace Euronext Shares tendered in the Sales Facility |
As from 26 July 2024 |
Settlement of the proceeds of the Sales Facility to the relevant financial intermediary |
As soon as possible after receipt of the proceeds of the Sales Facility |
Delisting |
|
Last day of trading of GE Aerospace Euronext Shares on Euronext Paris |
24 July 2024 |
Delisting of GE Aerospace Euronext Shares on Euronext Paris |
25 July 2024 |
GE Aerospace shareholders participating in the Sales Facility are reminded that they acknowledge and accept (i) the risk implied from the change in the share market price and/or applicable exchange rates between the date on which their shares are delivered to Uptevia for participation in the Sales Facility and the receipt of the applicable average sale proceeds, and (ii) that from the time the GE Aerospace Euronext Shares are delivered to Uptevia, they will not be entitled to any subsequent dividend declared by GE Aerospace. They are also reminded that any orders to tender GE Aerospace Euronext Shares to the Sales Facility are irrevocable, as is the subsequent sale of such GE Aerospace Euronext Shares tendered on the NYSE.
Shareholders may request any additional information from their custodian and usual financial intermediary, who has received the details of the Delisting.
About GE AEROSPACE
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 44,000 commercial and 26,000 military aircraft engines. With a global team of 52,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow and the future at www.geaerospace.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240618573691/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
